DALLAS, Aug. 14, 2020 /PRNewswire/ -- Lantern Pharma
(NASDAQ: LTRN), a clinical stage biotechnology company using its
proprietary RADR® artificial intelligence ("A.I.")
platform to improve drug discovery and development, and identify
patients who will benefit from its portfolio of targeted oncology
therapeutics, today announced that an interview with its CEO and
President Panna Sharma will air
on The RedChip Money Report television program.
The interview will air Sunday, August 16,
2020 at 6 p.m. local time on
Bloomberg International, available in 100+ million homes across
Europe.
In the exclusive interview, Sharma discusses the Company's
innovative A.I.-based drug discovery and development platform, how
it is being actively deployed, and current clinical testing
underway.
To view the interview segment, please
visit: https://youtu.be/zLWayWYBl8k
The interview will also air in the U.S. on the Action Channel on
Sunday, August 16, 2020 at
11 a.m. ET and is available via on
demand stream on American Business TV.
"The RedChip Money Report" delivers insightful commentary on
small-cap investing, interviews with Wall Street analysts,
financial book reviews, as well as featured interviews with
executives of public companies.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical
company innovating the repurposing, revitalization and development
of precision therapeutics in oncology. We leverage advances in
machine learning, genomics, and artificial intelligence by using a
proprietary A.I. platform to discover biomarker signatures that
help identify patients more likely to respond to our pipeline of
cancer therapeutics. Lantern's focus is to improve the outcome for
patients by leveraging our technology to uncover, rescue and
develop abandoned or failed drugs. Our current pipeline of three
drugs, with two programs in clinical stages and two in preclinical,
focuses on cancers that have unique and unmet clinical needs with a
clearly defined patient population. We believe that the use of
machine learning, genomics and computational methods can help
accelerate the revitalization, refocusing and development of small
molecule-based therapies. By targeting drugs to patients whose
genomic profile identifies them as having the highest probability
of benefiting from the drug, this approach represents the potential
to deliver best-in-class outcomes. Our team seeks out experienced
industry partners, world-class scientific advisors, and innovative
clinical-regulatory approaches to assist in delivering cancer
therapies to patients as quickly and efficiently as possible. For
more information, please visit the company's website
at www.lanternpharma.com or follow the company on Twitter
@lanternpharma.
Contact:
Marek Ciszewski, JD
Director, Investor Relations
628-777-3167
Forward-looking Statements
This press release and the interview referenced in this press
release contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements include, among other things, statements
relating to: the potential advantages of our
RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates; estimates regarding the development timing for our drug
candidates; our strategic plans to expand the number of data points
that our RADR® platform can access and analyze; our
research and development efforts of our internal drug discovery
programs and the utilization of our RADR® platform
to streamline the drug development process; and our intention to
leverage artificial intelligence, machine learning and genomic data
to streamline the drug development process and to identify patient
populations that would likely respond to a drug candidate. Any
statements that are not statements of historical fact (including,
without limitation, statements to the effect that Lantern Pharma
Inc. or our management "believes," "expects," "anticipates,"
"estimates," "plans" (and similar expressions) should be considered
forward-looking statements. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as the impact of
the COVID-19 pandemic, the results of our clinical trials, and the
impact of competition. Additional factors can be found in the Risk
Factors section in our final prospectus, dated June 10, 2020, for our initial public offering,
on file with the Securities and Exchange Commission. You may access
our June 10, 2020 final prospectus
under the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov.
Given these risks and uncertainties, we can give no assurances that
our forward-looking statements will prove to be accurate, or that
any other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements made by us in this press release or in
the interview referenced in this press release represent our
judgment as of the date of such statement, and, except as otherwise
required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-301112622.html
SOURCE Lantern Pharma